Thiel-backed psychedelics firm Atai valued at $3.2bn in US debut
Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, jumped 40% in their US stock market debut
18 June 2021 - 18:18
Shares of Atai Life Sciences BV, backed by billionaire investor Peter Thiel, jumped 40% in their US stock market debut on Friday, giving the German psychedelics start-up a market capitalisation of $3.19bn.
The Berlin-based biotech start-up, which is exploring the use of psychedelic treatments for mental illnesses, raised $225m from selling 15 million shares in its upsized initial public offering (IPO) on Thursday...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.